Library

By pinki shah / May 14, 2022

Displaying 1,126 - 1,150 of 2,995

By: Mohamed A. Kharfan-Dabaja, MD, MBA

Chimeric Antigen Receptor (CAR) T Cell Therapy - Progress and Challenges

Chimeric Antigen Receptor (CAR) T Cell Therapy - Progress and Challenges

By: Mohamed A. Kharfan-Dabaja, MD, MBA, FACP

Management of Metastatic Breast Cancer

Management of Metastatic Breast Cancer

By: Noridza Rivera-Rodriguez, MD

Myelodysplasia and Secondary AML

Myelodysplasia and Secondary AML

By: Rami Komrokji, MD

Melanoma: Beyond Checkpoint Inhibitors

Melanoma: Beyond Checkpoint Inhibitors

By: Sanjiv S. Agarwala, MD

Multiple Myeloma Transplant and Non-transplant Modalities

Multiple Myeloma Transplant and Non-transplant Modalities

By: Sikander Ailawadhi, MD

Lymphoma: State of the Art

Lymphoma: State of the Art

By: Alexey Danilov, MD, PhD

Lymphoma: State of the Art

Lymphoma: State of the Art

By: Alexey Danilov, MD, PhD

Clinical Update: Malignant Hematology

Clinical Update: Malignant Hematology

By: Atis Barzdins, MD

DLBCL & Hodgkin’s Disease: Novel Approaches

DLBCL & Hodgkin’s Disease: Novel Approaches

By: Eduardo Sotomayor, MD

Hematology Session III

Hematology Session III

By: Francine Foss, Eduardo Sotomayor, Nakhle Saba

T-Cell NHL: What’s New?

T-Cell NHL: What’s New?

By: Francine M. Foss, MD

CLL: Novel Therapies

CLL: Novel Therapies

By: Javier Pinilla-Ibarz, MD

Novel Therapies for Aggressive Non-Hodgkin Lymphomas

Novel Therapies for Aggressive Non-Hodgkin Lymphomas

By: Kami J. Maddocks, MD

CAR-T Cell as Strategy for the Management of Hematologic Malignancies

CAR-T Cell as Strategy for the Management of Hematologic Malignancies

By: Krishna Komanduri, MD

Other Driver Mutations: cMET, B-RAF, RET, NTRK

Other Driver Mutations: cMET, B-RAF, RET, NTRK

By: Luis E. Raez, MD, FACP, FCCP

Current Status of CAR-T Therapy in Hematology

Current Status of CAR-T Therapy in Hematology

By: Matthew Matasar, MD

Current Status of CAR-T Therapy in Hematology

Current Status of CAR-T Therapy in Hematology

By: Matthew Matasar, MD

Lymphoma and CLL 2024 Updates

Lymphoma and CLL 2024 Updates

By: Maxwell M. Krem, MD, PhD

Lymphoma and CLL 2024 Updates

Lymphoma and CLL 2024 Updates

By: Maxwell M. Krem, MD, PhD

Updates on FL and CLL from the ASH 2021 Meeting

Updates on FL and CLL from the ASH 2021 Meeting

By: Mazyar Shadman, MD, MPH

Chimeric Antigen Receptor T-Cell Therapy: Indications and Remaining Challenges

Chimeric Antigen Receptor T-Cell Therapy: Indications and Remaining Challenges

By: Mohamed Kharfan-Dabaja, MD

Treatment of Patients Progressing after BTKi and BCL2i

Treatment of Patients Progressing after BTKi and BCL2i

By: Nitin Jain, MD

AML and MDS: New Directions

AML and MDS: New Directions

By: Olatoyosi Odenike, MD

AML and MDS: New Directions

AML and MDS: New Directions

By: Olatoyosi Odenike, MD